Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement will employ Biocept’s cerebrospinal fluid assay CNSide1 in Plus Therapeutics’ ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), which is cancer in the membrane...
Brand Name : 186RNL
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2022
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?